Lizarraga Ingrid, Schroeder Mary C, Weigel Ronald J, Thomas Alexandra
Department of Surgery, University of Iowa, Iowa City, IA, USA.
Department of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, Iowa City, IA, USA.
Ann Surg Oncol. 2015 Dec;22 Suppl 3(Suppl 3):S566-72. doi: 10.1245/s10434-015-4591-3. Epub 2015 May 9.
Although locoregional recurrence is known to affect overall survival for operable breast cancer, the impact of receptor status on locoregional control is debated. Currently, hormone receptor (HR) and human epidermal growth factor receptor-2 (HER2) status are generally not considered relevant to surgical choice. This study examines recent population-level surgical trends with regard to receptor status.
We used the Surveillance, Epidemiology, and End Results (SEER) data to identify stage I-III female breast cancers diagnosed from 2010 to 2011. Patients were categorized by HR and HER2 receptor status. Univariate and multivariate logistic regressions were used to assess factors associated with undergoing mastectomy and the choice of contralateral prophylactic mastectomy (CPM).
The overall mastectomy rate for the 87,504 women diagnosed in 2010-2011 was 43.4 %. On multivariate analysis, the odds of receiving mastectomy was greater for HER2-positive disease with either HR-negative or HR-positive status, than for women with HER2-negative/HR-positive disease (odds ratio 1.73 and 1. 31, respectively; all p values <0.001). Age, stage, marital status, race, and year of diagnosis also correlated with mastectomy. Triple-negative breast cancer (TNBC) was associated with CPM, while HER2 status was not. The mastectomy rate, which increased overall from 2006 to 2010, has continued to increase for stage III disease but has decreased for stage I disease. Mastectomy rates overall were lower in 2011 than 2010 (p = 0.012).
HER2-positive disease and TNBC were independent predictors of more extensive surgery in this large, recent, population-based cohort. Although mastectomy rates have continued to increase for stage III disease, mastectomy rates overall were lower in 2011 than in previous years.
虽然已知局部区域复发会影响可手术乳腺癌患者的总生存期,但受体状态对局部区域控制的影响仍存在争议。目前,激素受体(HR)和人表皮生长因子受体2(HER2)状态通常被认为与手术选择无关。本研究探讨了近期基于人群的手术趋势与受体状态之间的关系。
我们使用监测、流行病学和最终结果(SEER)数据,确定2010年至2011年诊断为I - III期的女性乳腺癌患者。患者按HR和HER2受体状态进行分类。单因素和多因素逻辑回归用于评估与接受乳房切除术及对侧预防性乳房切除术(CPM)选择相关的因素。
2010 - 2011年确诊的87,504名女性的总体乳房切除率为43.4%。多因素分析显示,HER2阳性且HR阴性或HR阳性疾病的患者接受乳房切除术的几率,高于HER2阴性/HR阳性疾病的女性(比值比分别为1.73和1.31;所有p值<0.001)。年龄、分期、婚姻状况、种族和诊断年份也与乳房切除术相关。三阴性乳腺癌(TNBC)与CPM相关,而HER2状态则不然。乳房切除率在2006年至2010年总体呈上升趋势,III期疾病持续上升,但I期疾病有所下降。2011年的总体乳房切除率低于2010年(p = 0.012)。
在这个近期基于人群的大型队列中,HER2阳性疾病和TNBC是更广泛手术的独立预测因素。虽然III期疾病的乳房切除率持续上升,但2011年的总体乳房切除率低于前几年。